2024 |
Genmab - ADR
|
Executive Vice President, Chief Medical Officer and Head of Experimental Medicines |
25.8 M |
30.3 % |
2023 |
Genmab - ADR
|
Executive Vice President, Chief Medical Officer and Head of Experimental Medicines |
19.8 M |
- |
2022 |
Genmab - ADR
|
- |
15.2 M |
- |
2022 |
Genmab - ADR
|
Executive Vice President, Chief Medical Officer and Head of Experimental Medicines |
- |
- |
2021 |
Genmab - ADR
|
- |
10.9 M |
- |
2021 |
Genmab - ADR
|
Executive Vice President, Chief Medical Officer and Head of Experimental Medicines |
- |
- |
2020 |
Genmab - ADR
|
Executive Vice President, Chief Medical Officer and Head of Experimental Medicines |
- |
- |
2019 |
Genmab - ADR
|
Senior Vice President and Head of Oncology |
- |
- |
2018 |
Genmab - ADR
|
Senior Vice President, Oncology and Translational Medicine |
- |
- |